23rd Jan 2014 09:30
For immediate release | 23 January 2014 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
TR-1: Notification of Major Interest in Shares
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | Alliance Pharma plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): |
On market transfer between direct and indirect funds
| x | ||
3. Full name of person(s) subject to thenotification obligation: | Aviva plc & its subsidiaries | |||
4. Full name of shareholder(s) (if different from 3.): | Registered Holder:
BNY (Nominees)Limited 212,570*
BNY Norwich Union Nominees Limited 2,785,299*
Chase (GA Group) Nominees Limited 19,974,014*
Vidacos Nominees Limited 157,711*
*denotes direct interest
Chase Nominees Limited 956,282
| |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 21 January 2014 | |||
6. Date on which issuer notified: | 22 January 2014 | |||
7. Threshold(s) that is/are crossed orreached: | 9% to 8% Change at Direct Interest Level | |||
8. Notified details: | |||||||||||
A: Voting rights attached to shares | |||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | |||||||
Direct | Direct | Indirect | Direct | Indirect | |||||||
Ordinary SharesGB0031030819 | 24,316,755 | 24,316,755 | 24,085,876 | 23,129,594 | 956,282 | 8.76% | 0.36% | ||||
B: Qualifying Financial Instruments | |||||||||||
Resulting situation after the triggering transaction | |||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | |||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |
| Nominal | Delta | ||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
24,085,876 | 9.12% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | Figures are based on a total number of voting rights of 264,080,873 as per the Company's CULS Conversion and Additional Listing Announcement of 19 December 2013.
| |
14. Contact name: | Neil Whittaker, Aviva plc | |
15. Contact telephone number: | 01603 684420 | |
Related Shares:
Alliance PharmaAviva